Colon Cancer (CC) is common type of the intestinal cancers, it's onset in peoples at 50-70 years and high percent in male more than female and account for about 80% of all intestinal cancer cases CC diagnoses depend on histopathological finds of abnormal colon architectures in the tissue as golden standard of CC diagnosis. Trophoblast cell surface antigen 2 (TROP2) or tumor-associated calcium signal transducer 2 (TACSTD2) is a 36-kDa type I transmembrane glycoprotein and exerts dual functions as an oncogene and tumor suppressor in cancer cells is transmembrane glycoprotein receptor, encoded by Tacstd2 gene, observe in various cancer types of especially epithelial cancers. TROP2 has the up-regulation (overexpression) in another cancer cells such as pancreatic, thyroid and ovarian cancers. It is shown up-regulation of TROP 2 in CC Iraqi patients by Immunohistochemical method. The current study done in Al-Yarmook Teaching Hospital from March 2019 to January 2021, was included 30 cases of CC patients ( 23 males and 7 females) and 30 healthy subjects (23 males and 7 females), all of subject's age were more than 50 years. This study depends on collect of paraffin embedded CC biopsies then used Immunohistochemical method to examine the present of TROP2 in all cases. This qualitative study shows significant expression of TROP2 in CC patients compare with control groups. The present study confirm effect of TROP2 expression on CC development.